Psychosis Clinical Trials

138 recruitingLast updated: June 18, 2026

There are 138 actively recruiting psychosis clinical trials across 47 countries. Studies span Not Applicable, Phase 3, Phase 4, Phase 2, Phase 1, Early Phase 1. Top locations include Houston, Texas, United States, Miami, Florida, United States, Montreal, Quebec, Canada. Updated daily from ClinicalTrials.gov.


Psychosis Trials at a Glance

138 actively recruiting trials for psychosis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Not Applicable with 72 trials, with the heaviest enrollment activity in Houston, Miami, and Montreal. Lead sponsors running psychosis studies include Northwell Health, Pakistan Institute of Living and Learning, and Douglas Mental Health University Institute.

Treatments under study

About Psychosis Clinical Trials

Looking for clinical trials for Psychosis? There are currently 91 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Psychosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Psychosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 138 trials

Recruiting
Phase 2Phase 3

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled145 locationsNCT06159673
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company500 enrolled154 locationsNCT06126224
Recruiting
Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company800 enrolled428 locationsNCT05980949
Recruiting
Not Applicable

FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early Psychosis

PsychosisSchizophrenia Spectrum Disorders (SSD)First-episode Psychosis+4 more
Stephanie Mehl252 enrolled8 locationsNCT07645443
Recruiting
Not Applicable

Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode

First-episode Psychosis
University Hospital, Brest217 enrolled5 locationsNCT05384392
Recruiting
Not Applicable

Psychoeducation Program for Family Caregivers Coordinated by an APRN

Caregiver BurdenFirst Episode Psychosis (FEP)Nurse Practitioners+1 more
Hôpital le Vinatier180 enrolled5 locationsNCT07041463
Recruiting
Phase 1Phase 2

A Study Exploring Changes in a Variety of Biomarkers Following Dosing With MT1988 in Participants at Clinical High Risk for Psychosis

Clinical High Risk for Psychosis (CHR)
Monument Therapeutics Limited150 enrolled15 locationsNCT07226895
Recruiting
Phase 3

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled22 locationsNCT06947941
Recruiting

Semantic and Syntactic Computerized Analysis of Free Speech

Psychotic DisordersPsychosisSchizophrenia and Related Disorders+2 more
University Hospital, Brest215 enrolled3 locationsNCT03525054
Recruiting
Not Applicable

Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

SchizophreniaCannabis UsePsychosis+1 more
Vanderbilt University Medical Center100 enrolled1 locationNCT07196462
Recruiting
Phase 2

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Lewy Body Dementia Psychosis
ACADIA Pharmaceuticals Inc.180 enrolled56 locationsNCT07029581
Recruiting
Not Applicable

mHealth for Early Psychosis Caregivers in Statewide Program Outreach

CaregiverCaregiver DistressFamily Caregivers+1 more
University of North Carolina, Chapel Hill30 enrolled1 locationNCT07225179
Recruiting
Phase 4

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Psychosis; Acute
Northwell Health120 enrolled1 locationNCT07483294
Recruiting
Not Applicable

Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use

Cognitive DysfunctionPsychotic DisordersCannabis Use+5 more
Douglas Mental Health University Institute134 enrolled1 locationNCT05445180
Recruiting
Not Applicable

Recovery With Exogenous Ketones and Antipsychotics

First-episode Psychosis
Université de Sherbrooke15 enrolled1 locationNCT07122531
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled40 locationsNCT06887192
Recruiting
Not Applicable

Neurobehavioral Mechanisms of Social Isolation and Loneliness in Serious Mental Illness

SchizophreniaPsychosis
Massachusetts General Hospital120 enrolled1 locationNCT04940663
Recruiting

Digital Strategies to Advance Help-Seeking Aim 1 and 2

Early PsychosisFirst-episode PsychosisClinical High Risk
Columbia University25,000 enrolled1 locationNCT06774430
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics, Inc., a Bristol Myers Squibb company410 enrolled116 locationsNCT05511363
Recruiting
Phase 4

Examining the Effects of Estradiol on Neural and Molecular Response to Reward

DepressionAnhedoniaPsychosis
University of North Carolina, Chapel Hill103 enrolled1 locationNCT05282277